Roivant brings rare disease program closer as Immunovant CEO retires

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its drugs to the FDA despite a Phase 3 win. The biopharma company will move to ...

Apr 21, 2025 - 12:03

Roivant brings rare disease program closer as Immunovant CEO retires

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its drugs to the FDA despite a Phase 3 win. The biopharma company will move to ...